SrasV1, France, Analysis, bibRecord, 000289

Interferons at age 50: past, current and future impact on biomedicine

Identifieur interne : 000289 ( France/Analysis ); précédent : 000288; suivant : 000290

Interferons at age 50: past, current and future impact on biomedicine

Auteurs : Ernest C. Borden [États-Unis] ; Ganes C. Sen [États-Unis] ; Gilles Uze [France] ; Robert H. Silverman [États-Unis] ; Richard M. Ransohoff [États-Unis] ; Graham R. Foster [Royaume-Uni] ; George R. Stark [États-Unis]

Source :

Nature Reviews Drug Discovery [ 1474-1776 ] ; 2007-12.

RBID : ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E

Abstract

The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.

Url:

DOI: 10.1038/nrd2422

Affiliations:

Links to Exploration step

ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferons at age 50: past, current and future impact on biomedicine</title>
<author><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
</author>
<author><name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
</author>
<author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
</author>
<author><name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
</author>
<author><name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
</author>
<author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
</author>
<author><name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1038/nrd2422</idno>
<idno type="url">https://api.istex.fr/ark:/67375/GT4-KRH340F0-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F25</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F25</idno>
<idno type="wicri:Area/Istex/Curation">001F25</idno>
<idno type="wicri:Area/Istex/Checkpoint">001312</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001312</idno>
<idno type="wicri:doubleKey">1474-1776:2007:Borden E:interferons:at:age</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097588</idno>
<idno type="RBID">PMC:7097588</idno>
<idno type="wicri:Area/Pmc/Corpus">000556</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000556</idno>
<idno type="wicri:Area/Pmc/Curation">000556</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000556</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000F41</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F41</idno>
<idno type="wicri:Area/Ncbi/Merge">001B29</idno>
<idno type="wicri:Area/Ncbi/Curation">001B29</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B29</idno>
<idno type="wicri:doubleKey">1474-1776:2007:Borden E:interferons:at:age</idno>
<idno type="wicri:Area/Main/Merge">003B23</idno>
<idno type="wicri:Area/Main/Curation">003968</idno>
<idno type="wicri:Area/Main/Exploration">003968</idno>
<idno type="wicri:Area/France/Extraction">000289</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Interferons at age 50: past, current and future impact on biomedicine</title>
<author><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CNRS UMR 5235, Place Eugene Bataillon, Montpellier, Cedex 5 FR34095</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Institute of Cell and Molecular Science, Queen Mary's School of Medicine, 4 Newark Street, London E1 4AT</wicri:regionArea>
<wicri:noRegion>London E1 4AT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Nature Reviews Drug Discovery</title>
<idno type="ISSN">1474-1776</idno>
<idno type="eISSN">1474-1784</idno>
<imprint><publisher>Nature Publishing Group</publisher>
<date when="2007-12">2007-12</date>
<biblScope unit="vol">6</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="975">975</biblScope>
<biblScope unit="page" to="990">990</biblScope>
<date type="Copyright" when="2007">2007</date>
</imprint>
<idno type="ISSN">1474-1776</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1474-1776</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
</region>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
</noRegion>
<name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
<name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
<name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
<name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000289 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000289 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E
   |texte=   Interferons at age 50: past, current and future impact on biomedicine
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Interferons at age 50: past, current and future impact on biomedicine

Interferons at age 50: past, current and future impact on biomedicine

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.